KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

NCT03662126 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

385

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)

Interventions

DRUG: KRT-232
DRUG: Best Available Therapy (BAT)

Sponsor

Kartos Therapeutics, Inc.